Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Vega-Beyhart, et al., PMID 40165498
Related Questions
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
What factors do you consider when deciding what type of glucagon preparation to prescribe for rescue hypoglycemia in patients with diabetes on insulin therapy?
Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
Does injectable semaglutide have a higher glucose-lowering efficiency than oral semaglutide?
How do you counsel patients on the use of berberine to prevent the progression of prediabetes to type 2 diabetes mellitus?
Is there a role for intermittent fasting as part of the management of a patient with long-standing type 2 diabetes and consistently poor glycemic control despite maximal therapy?
